Please assess the completion status of the following clinical trial:

Trial Title: Aerosolized Surfactant in Neonatal RDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants admitted to the NICU at Hutzel Women's Hospital (HWH)/Children's Hospital of Michigan (CHM)~2. Gestational age of 240/7-366/7 weeks~3. Postnatal age ≤ 24 hours~4. Clinical diagnosis of RDS based on (i) presence of at least two of the four classic symptoms (need of supplemental oxygen, tachypnea, intercostal retractions or grunting), and (ii) exclusion of other causes of respiratory failure and (iii) Clinician intent to administer surfactant if infant requires intubation~5. Respiratory support with NIV (CPAP or NIPPV or HFNC) with FiO2 ≥25% or PEEP ≥ 4 cmH20 or HFNC rate ≥ 2 LPM for ≤8 hours~6. Written informed consent from parent/guardian~Exclusion Criteria:~1. Previous receipt of surfactant~2. Infants with respiratory distress who are unstable and require immediate intubation~3. Active air leak syndrome (e.g. pneumothorax, pneumomediastinum)~4. Lethal congenital malformations; death anticipated within first 3 days of life; decision to withhold support~5. Serious abdominal, cardiac, airway or respiratory malformations including tracheal esophageal fistula, intestinal atresia, omphalocele, gastroschisis, pulmonary hypoplasia, or diaphragmatic hernia~6. Neuromuscular disorder resulting in respiratory compromise

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- Dose Schedule I (Type: ACTIVE_COMPARATOR): Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:1
- Dose Schedule II (Type: ACTIVE_COMPARATOR): Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:2
- Dose Schedule III (Type: ACTIVE_COMPARATOR): Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:1
- Dose Schedule IV (Type: ACTIVE_COMPARATOR): Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:2

Based on this trial design, predict the completion outcome and termination type (if applicable).